drugset / Trial / NCT01940991

Efficacy and Safety of Botulinum Toxin Type A for Moderate to Severe Crow's Feet Lines

NCT01940991 ↗

Phase 2 Completed 82 enrolled Revance Therapeutics, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

This study will confirm the efficacy and safety of a single topical administration of botulinum toxin type A compared to placebo control for the treatment of moderate to severe crow's feet lines

Timeline

Start
2013-08
Primary completion
2013-11
Completion
2013-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Botulinum toxin type A Protein / enzyme biologic — Topical

Indications